{"id":3911,"date":"2024-07-01T11:00:35","date_gmt":"2024-07-01T02:00:35","guid":{"rendered":"https:\/\/www.nanomrna.co.jp\/en\/?page_id=7"},"modified":"2025-12-22T14:18:48","modified_gmt":"2025-12-22T05:18:48","slug":"company","status":"publish","type":"page","link":"https:\/\/www.nanomrna.co.jp\/en\/company\/","title":{"rendered":"About NANO MRNA"},"content":{"rendered":"<div class=\"boxInner\">\n<p class=\"pgtit_8\"><span class=\"font_1\">NANO MRNA<\/span> is evolving a cycle of <span class=\"font_2\">mRNA medicine<\/span> <span class=\"font_3\">IP generation-licensing<\/span> as a platform company that connects drug discovery seeds with medical and drug development needs.<\/p>\n<\/div>\n<div id=\"profile\" class=\"pagenailink\"><\/div>\n<div class=\"boxInner\">\n<h2>Corporate Profile<\/h2>\n<table id=\"hyobox\" class=\"profile_hyo\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<th>Corporate Nam<\/th>\n<td>NANO MRNA Co.,Ltd.<\/td>\n<\/tr>\n<tr>\n<th>Location<\/th>\n<td>\n<div class=\"mb10\">\n<h5>Tokyo Office (Head office)<\/h5>\n<p class=\"mb10\">Atago Green Hills MORI Tower 26F<br class=\"\"><br \/>\n2-5-1 Atago, Minato-ku, Tokyo<br class=\"\"><br \/>\nTEL: +81 (0)3-6432-4791<br class=\"\">FAX: +81 (0)3-6432-4794<\/p>\n<div class=\"linktext\"><a href=\"https:\/\/www.nanomrna.co.jp\/en\/company\/map#map01\">Map<\/a><\/div>\n<\/div>\n<div>\n<h5>Lab<\/h5>\n<p class=\"mb10\">Shonan Health Innovation Park (ADDP)<br class=\"\"><br \/>\n26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012<\/p>\n<div class=\"linktext mb10\"><a href=\"https:\/\/www.nanomrna.co.jp\/en\/company\/map#map03\">Map<\/a><\/div>\n<\/div>\n<\/td>\n<\/tr>\n<tr>\n<th>Subsidiary Company<\/th>\n<td><a href=\"https:\/\/www.nanomrna.co.jp\/en\/company\/group#gp01\">PrimRNA Co., Ltd.<\/a><\/td>\n<\/tr>\n<tr>\n<th>Establishment<\/th>\n<td>June 14, 1996<\/td>\n<\/tr>\n<tr>\n<th>Capital<\/th>\n<td>166 million yen (As of June 27, 2025)<\/td>\n<\/tr>\n<tr>\n<th>Number of employees &amp; management<\/th>\n<td>27 (As of June 27, 2025)<\/td>\n<\/tr>\n<tr>\n<th>Scopes of Business<\/th>\n<td>R&amp;D and production of pharmaceuticals using micellar nanoparticles technology.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"tobiracon\">\n<div class=\"tobirabox\">\n<div class=\"tobira_all_link\">\n<figure><img decoding=\"async\" src=\"https:\/\/www.nanomrna.co.jp\/en\/nanocms\/wp-content\/themes\/original\/img\/icon\/icon_6.svg\" \/><\/figure>\n<p>Access<\/p>\n<p><a href=\"https:\/\/www.nanomrna.co.jp\/company\/map\/\" target=\"_blank\" rel=\"noopener noreferrer\"><\/a>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>NANO MRNA is evolving a cycle of mRNA medicine IP generation-licensing as a platform company that connects dru [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":10,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/3911"}],"collection":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/comments?post=3911"}],"version-history":[{"count":85,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/3911\/revisions"}],"predecessor-version":[{"id":4685,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/3911\/revisions\/4685"}],"wp:attachment":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/media?parent=3911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}